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Background: Recently a new risk marker for drug-induced arrhythmias called index of cardio-
electrophysiological balance (iCEB), measured asQT interval divided byQRS duration, was evaluated
in an animal model. It was hypothesized that iCEB is equivalent to the cardiac wavelength λ (λ =
effective refractory period (ERP) x conduction velocity) and that an increased or decreased value
of iCEB would potentially predict an increased susceptibility to TdP or non-TdP mediated VT/VF,
respectively.
Methods: First, the correlation between QT interval and ERP was evaluated by invasively
measuring ERP during a ventricular stimulation protocol in humans (N = 40). Then the effect of
administration of sotalol and flecainide on iCEB was measured in 40 patients with supraventricular
tachycardias. Finally iCEB was assessed in carriers of a long QT syndrome (LQTS, N = 70) or Brugada
syndrome (BrS, N = 57) mutation and compared them with genotype negative family members
(N = 65).
Results: The correlation between QT interval and ERP was established (Pearson R2 = 0.25) which
suggests that iCEBERPxCVQT/QRS. Sotalol administration increased iCEB (+ 0.23; P = 0.01),
while it decreased with the administration of flecainide (–0.21, P = 0.03). In the LQTS group iCEB
was increased (5.22 ± 0.93, P < 0.0001) compared to genotype negative family members (4.24 ±
0.5), while it was decreased in the BrS group (3.52 ± 0.43, P < 0.0001).
Conclusions: Our data suggest that iCEB (QT/QRS) is a simple but effective ECG surrogate of
cardiac wavelength. iCEB is increased in situations that predispose to TdP and is decreased in
situations that predispose to non-TdP mediated VT/VF. Therefore, iCEB might serve as a noninvasive
and readily measurable marker to detect increased arrhythmic risk.
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date there is no comprehensive, easy to measure
and widely available risk marker available. The
QT interval is an ECG surrogate for action
potential duration and is the most widely used
ECG risk marker for arrhythmias.1 Prolonged QT
C© 2015 Wiley Periodicals, Inc.
DOI:10.1111/anec.12309
1
2  A.N.E.  xxxx 2015  Vol. 00, No. 0  Robyns et al.  iCEB as a New Biomarker of Arrhythmic Risk
interval is commonly used as a risk marker to
detect individuals prone to develop torsades de
pointes (TdP), a type of polymorphic ventricular
tachycardia (VT) or ventricular fibrillation (VF) in
the context of prolonged QTc. Patients at risk for
the development of nontorsadogenic VT/VF are not
identified if only QTc is evaluated, emphasizing the
need for additional biomarkers.
Recently a new noninvasive marker—index of
cardio-electrophysiological balance (iCEB) between
the depolarization and repolarization of the action
potential—was introduced as a potential risk
predictor of drug induced arrhythmia in rabbit
left ventricular wedge preparations.2 The rationale
for this parameter is that iCEB, measured as
QT interval divided by QRS duration, might
serve as an ECG-based derivative of cardiac
wavelength λ, which plays an important role in
arrhythmogenesis: drugs that increase wavelength
tend to increase the risk for TdP while agents
that decrease the wavelength tend to increase the
risk for non-TdP VT or VF.3–5 Cardiac wavelength
λ is the distance travelled by the depolarization
wave during the functional refractory period. A
local estimate of λ is determined by the product
of conduction velocity (CV) and effective refractory
period (ERP).6 QRS duration in absence of a typical
bundle branch block is inversely proportional
to CV within the cardiac ventricle. Conflicting
data exist on the association of QT interval and
ERP, requiring re-evaluation of its correlation.7–9
Nevertheless, from a theoretical point of view,
we would expect a correlation between action
potential duration (at the cellular level), ERP (at
the level of the whole tissue) and QT interval
(at the level of the surface ECG). Therefore we
hypothesize that QT/QRS is an easy to measure
ECG surrogate for cardiac wavelength (λ = CV ×
ERP or QT/QRS) and thus iCEB reflects the balance
between cardiac depolarization and repolarization
(Fig. 1).
It was already shown in isolated rabbit left
ventricle wedge preparations that iCEB, like λ,
is increased after administration of drugs that
predispose to TdP and that both iCEB and λ
were decreased after administration of drugs that
increase the risk for non-TdP VT/VF.2 As a follow-
up investigation, we evaluated the value of this
potential new biomarker in the clinical setting.
We first wanted to try and demonstrate the cor-
relation between uncorrected QT interval and ERP
measured invasively during an electrophysiological
Figure 1. Schematic overview of iCEB. Balance
and imbalance of the depolarization (QRS duration)
and repolarization (QT interval) of cardiac elec-
trophysiology. Schematic changes in the index of
cardio-electrophysiological balance (iCEB): significant
increase/decrease (↑ or ↓) in iCEB by increase/decrease
in QT interval or decrease/increase in QRS duration
could potentially be proarrhythmic for TdP- and non-
TdP mediated VT/VF respectively (imbalance of cardiac
electrophysiology). TdP = torsades de pointes; VT =
ventricular tachycardia; VF = ventricular fibrillation.
study (EPS). Subsequently, we wanted to see if
iCEB was altered in opposite directions in patients
after administration of a drug that predisposes
to TdP (sotalol) or to non-TdP mediated VT/VF
(flecainide).10–12 Finally, we wanted to assess the
value of this new biomarker in hereditary heart
disease, including congenital long QT syndrome
(LQTS), which predisposes to TdP, and Brugada
syndrome (BrS), which predisposes to non-TdP
mediated VT/VF.
METHODS
Study Population
In this retrospective single center study, we
tested our hypothesis in three different popula-
tions. Overall patients with a clear bundle branch
block were excluded from analysis. Our study
complied with the Declaration of Helsinki, and
the research protocol was approved by the locally
appointed ethics committee.
First we evaluated whether QT interval mea-
sured from the surface ECG and ERP measured
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during an electrophysiological study (EPS) are cor-
related. Therefore we analyzed the EPS database of
the university hospitals Leuven to identify Brugada
syndrome patients, according to the diagnostic
criteria stated by the recent expert consensus
document endorsed by the Heart Rhythm Society,
European Heart Rhythm Association and the Asia
Pacific Heart Rhythm Society, who underwent an
EPS between November 2009 and May 2014.13
We also included a cohort who were referred for
unexplained syncope or palpitations and were not
diagnosed with overt underlying cardiomyopathy,
primary arrhythmic heart disease or other diagno-
sis prior to EPS.
For our second goal we selected patients with
atrial arrhythmias followed at our arrhythmia
outpatient clinic who were started on either Sotalol
or Flecainide. We analyzed available ECG’s of
patients on and off drug treatment in order to
evaluate their effect on iCEB values.
The third patient population consisted of carriers
of a likely or confirmed pathogenic mutation
in one of the susceptibility genes for LQTS or
BrS, identified at the center for hereditary heart
disease of the university hospitals Leuven between
March 2003 and March 2014. We considered
patients carrying a (putative) pathogenic mutation
as having the disease, whether or not they were
phenotypically affected. Children younger than
8 years old were excluded because of pediatric
ECG variations. As controls we included genotype
negative family members of genotype positive
probands who were screened for LQTS or BrS.
Patients were classified as symptomatic if they
experienced abrupt (likely arrhythmic) syncope,
VT, VF or aborted sudden death. Patients in the
BrS group with atrial arrhythmias, severe AV
conduction impairment or sick sinus syndrome as
expression of their SCN5A disease were considered
asymptomatic. Brugada syndrome patients with
inducible VT during EPS without clinical events
were not considered as being symptomatic.
ECG Measurements
Twelve-lead ECG recordings were analyzed
by MUSE software (GE healthcare). Automated
measurements of QRS duration, QT interval and
heart rate were performed. Manual measurements
of the QT interval, measured as the intersection of
a tangent to the steepest slope of the last limb of
the T wave and the baseline, were subsequently
performed with high resolution calipers within the
MUSE software program. Signal averaged beats of
10 seconds of ECG of the precordial and peripheral
leads were superimposed to facilitate interval
delineation. The measurements were performed
on lead II and lead V5 and then the longest QT
interval was selected for analysis. QT interval
was corrected using both the Bazett (QTc =
QT/(RR1/2)) and Fridericia (QTc = QT/(RR1/3))
formulae.
Invasive ERP Measurements
During a ventricular stimulation protocol the
right ventricular apex or outflow tract were
stimulated eight times at a constant cycle length
(stimulation train) followed by a premature beat (S1
is basic stimulus, S2 is first premature stimulus).
The first S2 was given at a coupling interval of
400 ms and was shortened with 10 ms per step. The
ERP is defined as the longest premature coupling
interval S1–S2 that fails to produce a propagated
ventricular response. We evaluated the ERP at a
cycle length of 600 ms (100 BPM) stimulated at
the right ventricular apex. QT interval, RR interval
and QRS duration were manually measured at
the start of the electrophysiological study (EPS)
to allow correlation of QT and ERP measured
closely together. All measurements were done
with Labsystem Pro Recording System (Bard
Electrophysiology System).
Statistical Analysis
Data were analyzed within Microsoft Excel and
Graphpad Prism software programs. The artwork
was created with Graphpad prism. All continuous
variables are expressed as mean ± standard devi-
ation and as number (percentage) for categorized
variables. The association of ERP and QT was
assessed using a Pearson correlation. Univariate
comparisons were performed using the two-sided
t-test, one way ANOVA or chi-square test, where
appropriate. The effect of sotalol and flecainide
was evaluated by a paired t-test. Normality
testing was done with d’Agostino’s K-squared test.
P values below 0.05 were considered statistically
significant.
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Table 1. Results of Baseline ECG and Invasive ERP
Measurements during EPS in the Combined BrS and
“Others” Cohort
Value
N 40
Age 39 ± 15
RR (ms) 955 ± 197
QRS (ms) 103 ± 20
QT (ms) 376 ± 36
QTcB (ms) 388 ± 33
iCEB (QT/QRS) 3.76 ± 0.65
iCEBc (QTcB/QRS) 3.9 ± 0.75
QT/ERP 1.68 ± 0.14
QTc/ERP 1.74 ± 0.16
Data are represented as mean values ± SD. ERP = effective
refractory period; EPS = electrophysiological study; N =
number; Auto = automated measurement; c = rate corrected
value; B = corrected with Bazett’s formula; iCEB = index of
cardio-electrophysiological balance.
RESULTS
ERP-QT Correlation
We included 40 patients, 20 with BrS and
20 others, to evaluate the correlation of ERP
and QT. Final diagnosis in the 20 cases of
unexplained syncope or palpitations (“other” group
mentioned above) was sinus tachycardia in one,
atrial fibrillation in four, paroxysmal AV block
in one, AVNRT in two, RVOT VT in three
and vasovagal syncope in one. Definite diagnosis
remained elusive in eight patients. Both groups
consisted of 75% males, but the BrS group were
significantly older compared to the “other” group
(45 ± 13 versus 34 ± 15; P = 0.016).
Results of the ECG and EPS measurements
are summarized in Table 1. ERP and QT mea-
sured during EPS were significantly correlated
(Fig. 2). This correlation was more pronounced for
uncorrected QT interval compared to rate corrected
QT interval with Bazett’s formula (R2 0.25 vs.
0.12, respectively) and for QT measured during
EPS compared to measurements on standard ECG
a couple of hours before EPS (R2 0.25 vs. 0.12,
respectively). Rate uncorrected QT/QRSwas highly
correlated with ERP/QRS (R2 = 0.8; P < 0.0001),
as well as with rate corrected QTc/QRS (R2 =
0.77; P < 0.0001). There was no difference in ERP
between BrS patients and the control group (222
ms ± 18 vs. 227 ms ± 17; P = 0.37). These findings
support the use of uncorrected QT interval as a
surrogate for ERP. Consequently iCEB defined as
Figure 2. Correlation between ERP and QT. Pearson
correlation of invasively measured ERP during EPS and
QT measured at the beginning of EPS (N = 40): data
indicating that there is a moderate (R2 = 0.25) but highly
significant correlation between ERP and QT-interval (P =
0.001). ERP = effective refractory period; EPS =
electrophysiological study.
QT interval divided by QRS duration can be used as
the best available ECG based surrogate of cardiac
wavelength λ.
Effect of Sotalol and Flecainide on iCEB
(Table 2, Fig. 3)
We included 20 patients started on sotalol and
20 patients started on flecainide. Demographic data
are summarized in Table 2. Indication for flecainide
administration was atrial fibrillation in 12, AVNRT
in seven and atrial flutter in 1 while indication
for sotalol administration was atrial fibrillation in
19 and atrial flutter in one. After administration
of sotalol, iCEB significantly increased (mean
 +0.23, P = 0.01) while it significantly decreased
after administration of flecainide (mean  –0.21,
P = 0.03).
LQTS-BrS Group (Tables 3and4 and Figs.
4 and 5)
The total population in this cohort consisted
of 192 patients; 70 genotype positive LQTS
patients (21 patients with LQT1, 47 with LQT2
and 2 with LQT3), 57 genotype positive BrS
A.N.E.  xxxx 2015  Vol. 00, No. 0  Robyns et al.  iCEB as a New Biomarker of Arrhythmic Risk  5
Table 2. Clinical Characteristics in the Sotalol/Flecainide Group (upper part) and Effects of Sotalol and Flecainide
(lower part)
Sotalol Flecainide
N 20 20
Age 59 ± 9 50 ± 11
Males 11 (55%) 16 (80%)
Mean daily dose (mg) 160 ± 45 158 ± 61
Mean  P Value Mean  P Value
RR (ms) +38 ± 48 0.25 +34 ± 53 0.19
QRS (ms) +2.1 ± 4.9 0.12 +10 ± 4.2 <0.0001
QT auto (ms) +29 ± 11 0.0005 +22 ± 12 0.006
QTcB auto (ms) +20 ± 7.2 0.0005 +15 ± 6.8 0.004
JT auto (ms) +27 ± 10 0.0007 +12 ± 12 0.09
iCEB +0.23 ± 0.23 0.01 −0.2 ± 0.19 0.03
iCEBc (QTcB/QRS) + 0.15 ± 0.26 0.08 −0.28 ± 0.22 0.01
JTcB/QRS +0.18 ± 0.25 0.03 −0.26 ± 0.21 0.01
Data are represented as mean values ± SD for continuous variables and as number (percentage) for categorized variables.
Auto = automated measurement; B = corrected with Bazett’s formula; c = rate corrected value; iCEB = index of cardio-
electrophysiological balance.
Figure 3. Effect of sotalol and flecainide on iCEB. Effect of sotalol (left) and flecainide (right) on index of cardio-
electrophysiological balance (iCEB) in patients with paroxysmal supraventricular arrhythmias: data indicating that iCEB
was significantly increased after administration of sotalol (mean daily dose 160 mg; N = 20; P = 0.01) and decreased
after administration of flecainide (mean daily dose 158 mg; N = 20; P = 0.03).
Table 3. Clinical Characteristics of Genotype Negative Controls and Genotype Positive LQTS and BrS Patients
LQTS BrS
Controls Value P Value Value P Value
N 65 70 57
Mean age 38.3 ± 16 33.1 ± 16 0.06 36.5 ± 17 0.53
Males 33 (51%) 37 (53%) 0.81 26 (46%) 0.15
Beta-blocker therapy 10 (15%) 27 (39%) 0.025 9 (16%) 0.70
Symptomatic 0 (0%) 15 (21%) 10 (18%)
Data are represented as mean values ± SD for continuous variables and as number (percentage) for categorized variables.
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Table 4. ECG Results LQTS and BrS Group
LQTS BrS
Controls Mean P Value Mean P Value
RR (ms) 900 ± 153 928 ± 165 0.31 980 ± 148 0.15
QRS (ms) 93 ± 10 87 ± 11 0.0004 117 ± 18 <0.0001
QT auto (ms) 392 ± 30 448 ± 56 <0.0001 407 ± 30 0.009
iCEB (QT/QRS) 4.24 ± 0.5 5.22 ± 0.93 <0.0001 3.52 ± 0.43 <0.0001
QTcB auto (ms) 416 ± 23 467 ± 45 <0.0001 413 ± 33 0.59
iCEBc (QTcB/QRS) 4.51 ± 0.57 5.45 ± 0.86 <0.0001 3.58 ± 0.49 <0.0001
JT auto (ms) 299 ± 30 361 ± 57 <0.0001 289 ± 23 0.051
JTcB auto (ms) 317 ± 23 376 ± 46 <0.0001 294 ± 24 <0.0001
JTcB/QRS 3.44 ± 0.53 4.4 ± 0.86 <0.0001 2.56 ± 0.47 <0.0001
QTcB man (ms) 402 ± 27 468 ± 51 <0.0001 398 ± 40 0.61
QTcF man (ms) 393 ± 23 461 ± 53 <0.0001 396 ± 37 0.62
Data are represented as mean values ± SD. Auto = automated measurement; B = corrected with Bazett’s formula; c = rate
corrected value; F = corrected with Fridericia’s formula; iCEB = index of cardio-electrophysiological balance; man = manual
measurement
patients (all with mutations in SCN5A), and 65
genotype negative family members. Clinical and
demographic characteristics are summarized in
Table 3. 27 patients (47%) fulfilled the clinical
criteria for Brugada syndrome as defined by the
recent expert consensus document.13
Results of the ECG measurements are sum-
marized in Table 4. iCEB is significantly altered
in the opposite direction in LQTS and BrS
patients, regardless of use of QT correction or JT
instead of QT interval. In LQTS, the increase in
iCEB is mainly attributed to the increase in QT
interval, although QRS duration is also shortened
accentuating the effect on iCEB. However, the
decrease of 6 ± 2 ms in QRS duration is probably
not clinically significant. On the contrary, although
there was a modest prolongation of the QT interval
in BrS patients, the significant decrease in iCEB is
mainly driven by prolongation of the QRS interval.
The prolongation of the QT interval was due to both
QRS widening (JT interval was unchanged with
even a trend towards shorter JT) and the decrease
in heart rate (QTc was unchanged). In LQTS there
was a trend towards higher values of iCEB in beta
blocker treated patients (5.44 vs. 5.1; P = 0.13) due
to a slight decrease in QRS duration and increase in
QT interval. This probably reflects treatment with
a beta blocker in higher risk patients with a longer
QTc interval.
The 15 symptomatic LQTS patients (5 LQT1
and 10 LQT2) had a significantly prolonged
QTc interval, independent of measurement and
correction method (automatically measured QT
corrected with Bazett’s formula 509 ± 60 ms vs.
456 ± 30 ms, P < 0.0001), and increased iCEB
(5.99 ± 1.2 vs. 5.02 ± 0.72, P = 00002), compared
to asymptomatic genetically positive LQTS patients
(Fig. 5). In BrS patients no significant results
were obtained if symptomatic and asymptomatic
patients were compared, probably due to the
small sample size (only 10 symptomatic patients).
Furthermore iCEB in patients with a spontaneous
or drug induced Brugada type 1 ECG did not differ
from SCN5A mutation carriers not fulfilling BrS
diagnostic criteria (3.48 ± 0.45 vs. 3.55 ± 0.42;
P = 0.51). Analysis of LQTS patients according to
genotype (LQT1 versus LQT2) did not show any
significant results.
Normal Values of iCEB According to Age
and Gender
One of the main assumptions in the concept of
iCEB is the existence of a certain optimal “normal”
value for this parameter. The control group in
the cohort of hereditary heart disease patients
consisted of 65 genotype negative family members.
In this group iCEB was normally distributed
with a mean of 4.24 and standard deviation of
0.5, thus the reference range for this population
sample was 3.24–5.24. The sotalol/flecainide group
contained 40 patients with atrial arrhythmias
without evidence for other heart disease and thus
presumably having no major increased risk for
ventricular arrhythmias. Their mean combined
iCEB value pretreatment was 4.25 ± 0.63 and
thus a reference range of 2.99–5.51. There was no
significant difference in iCEB between these two
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Figure 4. iCEB in long QT syndrome and Brugada
syndrome. Index of cardio-electrophysiological balance
(iCEB; upper panel) and its rate-corrected values (iCEBc
(middle panel) and JTc/QRS (bottom panel)) in carriers
of (putative) pathogenic mutations in patients with
the congenital long QT syndrome (LQTS) and Brugada
syndrome (BrS): Data indicating that iCEB or heart-
rate corrected iCEB (iCEBc or JTc/QRS with Bazett’s
correction) is significantly increased in LQTS (N = 70; all
P < 0.0001) and significantly reduced in BrS (N = 57; all
P < 0.0001) versus genotype negative family members
(N = 65).
control groups (P = 0.94). As such, these findings
in two independent populations indeed suggest an
optimal value for this parameter. Combining these
two control populations resulted in a normally
distributed spread with normal value of 4.24 and
reference range of 3.14–5.35 (Fig. 6). Influences
of sex and age on iCEB are shown in Figure 7.
The higher iCEB values found in females were
due to both higher QT intervals, probably related
to the effect of sex hormones, and reduced QRS
duration, most likely associated with smaller hearts
in females.
DISCUSSION
We believe we are the first to present clinical
data on a potential new noninvasive risk marker
for ventricular arrhythmias called the index of
cardio-electrophysiological balance (iCEB). iCEB
is measured as the QT interval divided by the
QRS duration on the surface ECG. First, we
demonstrated the correlation between the ERP
measured during EPS and the uncorrected QT
interval, thus supporting the concept of this new
marker as an ECG surrogate for cardiac wave-
length. We then showed that this biomarker was
increased by a drug that predisposes towards TdP
(sotalol) and was also elevated in LQTS mutation
carriers. In contrast, iCEB decreased following
administration of flecainide, a drug associated with
an increased risk for non-TdP mediated VT/VF,
and was lower in patients carrying a putative
pathogenic BrS mutation, a hereditary arrhythmia
syndrome associated with sudden cardiac death
due to non-TdP mediated VT/VF.
Only limited in vitro data are available on cardiac
wavelength as a risk stratifier, mainly due to the
invasive nature to measure it.3–5 To address these
limitations we hypothesized that QT/QRS might
serve as a readily measurable local estimate of
cardiac wavelength and called this parameter the
“index of cardio-electrophysiological balance.” It
is generally accepted that QRS duration in the
absence of a clear bundle branch block is inversely
proportional to conduction velocity in the cardiac
ventricle.6 Data on the relationship between QT
interval and ERP date back to the 1970s. Guss
and colleagues observed similar effects of QT and
ERP on increased right ventricular pacing rates
during EPS, however a formal association test was
not performed.7 Similar results were obtained by
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Figure 5. iCEB as risk stratifier in long QT syndrome and Brugada syndrome.
Index of cardio-electrophysiological balance (iCEB) in symptomatic and
asymptomatic carriers of (putative) pathogenic long QT syndrome (LQTS)
mutations (left panel) and in symptomatic and asymptomatic carriers of
(putative) pathogenic Brugada syndrome (BrS) mutations (right panel). Data
indicating that there is a significant difference between the symptomatic
(N = 15) and asymptomatic LQTS patients (N = 55; P = 0.0002), but no signif-
icant difference between the symptomatic (N = 10) and asymptomatic (N = 47;
P = 0.32) BrS patients.
Olsson et al. who showed in 14 humans what they
called “a certain but poor relationship” by plotting
QTc versus ERP, yet a formal association test
was not performed.8 However, more recently Voss
et al. could not demonstrate a statistically signifi-
cant correlation between ERP and uncorrected or
rate corrected QT interval in 19 healthy dogs.9 We
evaluated the relationship between QT and ERP
in a far bigger cohort (N = 40) compared to these
previous studies. The study size might be one of
the reasons why we did find a significant, although
modest, correlation. Our findings demonstate the
potential utility of QT/QRS as an ECG based
derivative of cardiac wavelength.
Drug-induced arrhythmia has been the main
concern in drug development within the pharma-
ceutical industry over the last 20 years. Current
guidelines recommend a thorough QT clinical
study to evaluate the cardiac risk profile of
new drugs. However, there is some concern
regarding the use of QT interval as the sole
risk marker for drug-induced arrhythmias.14 It
has been shown that not all drugs that prolong
the QT interval are proarrhythmic, and absence
of QT prolongation is no guarantee for lack of
proarrhythmia.15 Therefore a search is ongoing for
better or complementary risk markers. Recently
iCEB was proposed as a new and noninvasive
biomarker to predict the risk for both TdP and
non-TdP VT/VF.2 It was suggested that an optimal
balance between depolarization (QRS duration) and
repolarization (QT interval) is crucial to preserve
the electrical stability of the ventricles: deviating
too much from this delicate balance may indeed be
proarrhythmic (Fig. 1). Administration of certain
drugs (e.g., sotalol and flecainide) and harboring a
(putative) pathogenic mutation in one of the LQTS
or BrS susceptibility genes are recognized situations
that increase the risk for either TdP or non-
TdP mediated VT/VF, respectively. iCEB, which
is altered in opposite directions in these situations
(sotalol and LQTS increase iCEB and flecainide and
BrS decrease iCEB) seems to support the hypothesis
of a delicate balance between depolarization and
repolarization. Patients with LQTS appeared to
have significantly elevated values of iCEB com-
pared to control subjects, and even higher values
in symptomatic patients, further suggesting that
increased iCEB might indicate enhanced risk for
TdP. Indeed iCEB is significantly higher in LQTS
patients, independent of genotype, contrastingwith
other proposed risk markers like Te-Tp that is only
increased in LQT2.16 In contrast in BrS patients the
iCEB value is significantly lower than in controls.
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Figure 6. iCEB in controls. Index of cardio-
electrophysiological balance in a control population
consisting of 65 genotype negative family members of
long QT syndrome and Brugada syndrome probands and
40 patients with atrial arrhythmias prior to start of either
flecainide or sotalol. Data demonstrating that iCEB is
normally distributed in this control population with a
reference range of 3.14–5.35.
Our BrS population was too small for a valid inves-
tigation of iCEB as risk marker for arrhythmias.
The question remains, however, why increased
iCEB (or λ) preferentially could lead to TdP,
as evident in LQTS and sotalol treated patients,
and decreased iCEB (or λ) preferentially could
lead to ventricular fibrillation, as observed in
BrS and flecainide treated patients. A possible
explanationmight be the underlying cellular effects
of these drugs and the underlying genetic cause
of the specific hereditary heart disease. Sotalol
is a drug with the combined effect of a beta-
blocker and a class III antiarrhythmic agent. The
class III properties are due to blocking of the
rapid component of the delayed rectifier potassium
current (IKr) and subsequent prolongation of phase
3 of the action potential and ERP.17 The most
common forms of congenital LQTS are either due
to loss of function of the slow (LQT1; KCNQ1 gene;
IKs) or rapid (LQT2; KCNH2 gene; IKr) component
of the delayed rectifier potassium current or
gain of function of the cardiac sodium channel
encoded by the SCN5A gene (LQT3; SCN5A
gene; INa). The underlying common mechanism
of action potential duration lengthening might
be resembled by an increase in iCEB. On the
other hand flecainide is well known for its
“bad” sodium channel blocking properties.18 The
BrS group in this study consisted of patients
with (putative) pathogenic mutations in SCN5A
causing a loss of function of the cardiac sodium
channel. So both treatment with flecainide and
BrS, caused by SCN5A mutations, result in a
reduced cardiac sodium channel function, reduced
sodium current and thus a reduced upstroke
velocity of phase 0 of the action potential.6 This
is observed as an increase in QRS duration on the
surface ECG recordings. This effect on the cardiac
sodium channel and action potential most likely is
the common mechanism for reduction in iCEB.
Limitations
The QT interval was confirmed as a noninvasive
measure of ERP, where measurement of the
QT interval was conducted at the beginning of
the EPS procedure. One could argue that the
QT measurement should have been done during
the stimulation train, but since QT hysteresis19
(adaptation of QT interval to sudden change in
heart rate) in men takes about 2 minutes we
decided to measure QT interval at the beginning
of the EPS in resting conditions with a stable
isoelectric line facilitating measurement of the end
of the T wave.
We evaluated iCEB in relation to LQTS or BrS
genotype. Since LQTS and BrS also exhibit the
phenomena of reduced penetrance and variable
expression typical for monogenic diseases, one
might state that the assumption that positive
genotype is equal to increased arrhythmia risk
is not entirely correct. However carriers of a
pathogenic mutation without clear expression of
the disease seem at increased risk of events.20
If multiple testing is taken into account in
both the LQTS/BrS and flecainide/sotalol cohort,
a Bonferroni correction would only classify
P values below 0.003 as statistically significant
(0.05/16 tests). Our observations in the LQTS/BrS
cohort tolerate this stringent correction method,
however the changes we detected in iCEB in
the flecainide/sotalol group would no longer be
significant. Since our work is mainly hypothesis
generating, we felt that a very stringent correction
for multiple testing was not indicated.
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Figure 7. iCEB according to gender and age. (A) Index of cardio-electrophysiological balance (iCEB) according to sex.
Females have a significantly increased value of iCEB compared to males (P < 0.0001). (B) iCEB according to different
age quartiles. Data demonstrating age has no major influence on iCEB. Bonferroni’s posttest indicated that no single
age group significantly differed from another age group.
Currently, iCEB defined as QT/QRS is not a
rate independent factor. However, some QRS rate
dependence (QRS shortening at higher heart rates)
is also present in healthy individuals.21 This effect
partially eliminates the effect of heart rate changes
on iCEB. Furthermore, the rate dependent effects
of Class I antiarrhythmic drugs are well known.18
This is evidenced by the widening of the QRS-
duration in a rate-dependent manner. Moreover,
QT rate dependence is highly individual in general
and it is especially disturbed in LQTS and BrS and
therefore a general heart rate correction formula
like Bazett’s formula is less reliable in these patient
populations.22–24 In our cohort, heart rate was
comparable in the hereditary heart disease group
and also in the patients treated with sotalol or
flecaı¨nide. However, individual risk stratification
based on this parameter might necessitate the
use of a rate corrected iCEB. For example, an
individual with a QT of 420 ms at a heart rate
of 100 BPM and a QRS of 100 ms has a normal
rate uncorrected iCEB value of 4.2, but a highly
abnormal rate corrected iCEB of 5.42. Therefore
the rate uncorrected iCEB will probably only be
useful in a specific heart rate range. Future follow-
up studies will also address this issue.
Finally, iCEB was not evaluated just prior to
onset of actual arrhythmic events. Instead we used
a surrogate for increased arrhythmia susceptibility,
specifically administration of two pro-arrhythmic
drugs and harboring mutations that predispose to
two pro-arrhythmic genetic diseases.
CONCLUSION
In conclusion, we propose iCEB as the best
practical ECG surrogate for λ and report here,
in this preliminary study, data of this parameter
for the first time in man. Increased potential risk
for TdP as observed with use of sotalol and in
congenital LQTS is associated with an increase
in iCEB. Increased potential risk for non TdP
mediated VT/VF as evident with use of flecainide
and in BrS is reflected by decreased iCEB. As
such, the main potential benefit of iCEB is the
detection of both increased risk to TdP and non-
TdP mediated VT/VF and therefore iCEB might
be a universal marker for ventricular arrhythmias.
Our findings need to be confirmed in future
prospective and adequately powered studies.
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